This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes
by Zacks Equity Research
Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
by Zacks Equity Research
According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
by Zacks Equity Research
ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.
Align (ALGN) Hurt by Dental Practice Closures, FX Headwind
by Zacks Equity Research
Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.
Here's Why Investors Should Retain Chemed (CHE) Stock Now
by Zacks Equity Research
Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.
LabCorp (LH) Rides on Innovations Amid Cost Constraints
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.
Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays
by Zacks Equity Research
Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
by Zacks Equity Research
Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod
by Zacks Equity Research
Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.
Here's Why Investors Should Retain Alcon (ALC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
Thermo Fisher (TMO) to Promote Mass Spectrometry Imaging
by Zacks Equity Research
Thermo Fisher's (TMO) new deal with TransMIT will advance the use of the AP-SMALDI5 AF ion source with Orbitrap MS technology for spatial multi-omics applications.
PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite
by Zacks Equity Research
PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.
Henry Schein (HSIC) Inks New Deal to Acquire Condor Dental
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of a Switzerland-based dental distribution company will strengthen its presence in the attractive European market.
Bruker (BRKR) to Advance 4D Proteomics With Latest Launch
by Zacks Equity Research
Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.
Here's Why Investors Should Retain Globus Medical (GMED) Now
by Zacks Equity Research
Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.
Neogen (NEOG) to Offer New Biosecurity Solution in Canada
by Zacks Equity Research
Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.
Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data
by Zacks Equity Research
Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
by Zacks Equity Research
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.